Healthcare products company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that new data from the Phase 3 MARIPOSA study will be presented at the 2025 European Lung Cancer Congress (ELCC).

The study shows that RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly improved median overall survival by more than one year compared to osimertinib in first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations.

Yusri Elsayed, M.D., Ph.D., Global Therapeutic Area Head, Oncology at Johnson & Johnson Innovative Medicine, said that the new data will transform treatment discussions and patient expectations. Henar Hevia, Ph.D., Senior Director, EMEA Therapeutic Area Lead, added that the chemotherapy-free regimen represents an innovative and life-extending option for patients.

Additional presentations will include data from the Phase 2 COCOON study evaluating a preventative dermatologic regimen, which met its primary endpoint and improved patient experience. The Phase 2 PALOMA-2 study, assessing the feasibility of switching to subcutaneous amivantamab, will also be highlighted.